Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 2Papillomavirus Infections 2Uterine Diseases 1Neoplasms 1Genital Diseases, Female 1

Interventions

anlotinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2temsirolimus 1olaparib 1niraparib 1Trabectedin 1Paclitaxel 1Ocoxin 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1GX-188 vaccine 1Filgrastim 1Dexamethasone 1Carboplatin 1CP protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Genital Diseases, Female × GX-188 vaccine × Clear all
NCT02139267 2017-07-12

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Genexine, Inc.

Phase 2 Completed
72 enrolled
Gynecologic

Uterine Cervical Dysplasia, Genital Diseases, Female, Neoplasms, Uterine Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡